Public, NASDAQ:SGEN
NASDAQ Global Market
Seattle Genetics, Inc -Premium Company Profile - New Research Report on Companies and Markets
Date: Fri, 14 Nov 2008 21:40:34 GMT
Tags:
Seattle Genetics, Inc -Premium Company Profile - New Research Report on Companies and Markets
Live-PR.com (Pressemitteilung) - Nov 14, 2008
Live-PR.com (Pressemitteilung) - Nov 14, 2008
Seattle Genetics is a clinical development stage biopharmaceutical company mainly focused on researching and developing monoclonal antibody - based therapies utilizing its proprietary monoclonal ...
Seattle Genetics to Present at the Oppenheimer HealthcareConference
Date: Wed, 29 Oct 2008 13:13:39 GMT
Tags:
Seattle Genetics to Present at the Oppenheimer HealthcareConference
MarketWatch - Oct 29, 2008
MarketWatch - Oct 29, 2008
, , ) announced today that Eric L . Dobmeier , Chief Business Officer , will present at the Oppenheimer 19th Annual Healthcare Conference on Tuesday , November 4 , 2008 , at 10 : 40 am Eastern ...
Seattle Genetics to Present at the Oppenheimer Healthcare Conference - Business Wire (press release)Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting
Date: Tue, 28 Oct 2008 16:10:25 GMT
Tags:
Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting
MarketWatch - Oct 28, 2008
MarketWatch - Oct 28, 2008
, , ) today presented preclinical data on SGN - 70 at the American College of Rheumatology ( ACR ) Annual Scientific Meeting in San Francisco , California.SGN - 70 is a humanized monoclonal antibody ...
American College of Rheumatology Annual Scientific Meeting - Business Wire (press release)Market Report -- In Play (SGEN)
Date: Fri, 24 Oct 2008 14:17:41 GMT
Tags:
Market Report -- In Play (SGEN)
MSN Money - Oct 24, 2008
MSN Money - Oct 24, 2008
Seattle Genetics preclinical data on antibody - drug conjugate programs Co announces data highlighting preclinical findings on two of its antibody - drug conjugate programs , SGN - 35 and SGN ...
Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs
Date: Fri, 24 Oct 2008 13:12:37 GMT
Tags:
Seattle Genetics Presents Preclinical Data on Antibody-Drug Conjugate Programs
Business Wire (press release) - Oct 24, 2008
Business Wire (press release) - Oct 24, 2008
BOTHELL , Wash . - - ( BUSINESS WIRE ) - - Seattle Genetics , Inc . ( NASDAQ : SGEN ) , today announced data highlighting preclinical findings on two of its antibody - drug conjugate ( ADC ) ...
SEATTLE GENETICS INC /WA Financials (EDGAR Online Financials)
Date: Fri, 14 Nov 2008 14:04:30 Etc/GMT
Tags:
SEATTLE GENETICS INC /WA Files SEC form 10-Q, Quarterly Report (EDGAR Online)
Date: Fri, 7 Nov 2008 21:17:26 Etc/GMT
Tags:
World's Scariest Stock: Dendreon (at Motley Fool)
Date: Fri, 31 Oct 2008 15:01:21 Etc/GMT
Tags:
Seattle Genetics to Present at the Oppenheimer Healthcare Conference (Business Wire)
Date: Wed, 29 Oct 2008 13:00:00 Etc/GMT
Tags:
Seattle Genetics Presents on SGN-70 at American College of Rheumatology Meeting (Business Wire)
Date: Tue, 28 Oct 2008 16:00:00 Etc/GMT
Tags:
BOTHELL, Wash.----Seattle Genetics, Inc. today presented preclinical data on SGN-70 at the American College of Rheumatology Annual Scientific Meeting in San Francisco, California. SGN-70 is a humanized monoclonal antibody targeting CD70 that is in development as a novel therapy for autoimmune diseases.